Vernakalant (RSD1235): a novel, atrial-selective antifibrillatory agent
- 20 March 2007
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Investigational Drugs
- Vol. 16 (4), 519-532
- https://doi.org/10.1517/13543784.16.4.519
Abstract
(2007). Vernakalant (RSD1235): a novel, atrial-selective antifibrillatory agent. Expert Opinion on Investigational Drugs: Vol. 16, No. 4, pp. 519-532. doi: 10.1517/13543784.16.4.519Keywords
This publication has 68 references indexed in Scilit:
- ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial FibrillationCirculation, 2006
- Comparing the guidelines: anticoagulation therapy to optimize stroke prevention in patients with atrial fibrillationJournal of the American College of Cardiology, 2004
- Atrial stunning: basics and clinical considerationsInternational Journal of Cardiology, 2003
- Increasing Trends in Hospitalization for Atrial Fibrillation in the United States, 1985 Through 1999Circulation, 2003
- ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summaryJournal of the American College of Cardiology, 2001
- Prevalence of Diagnosed Atrial Fibrillation in AdultsJAMA, 2001
- Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates 11Reprints are not available.The American Journal of Cardiology, 1998
- Correlation of symptoms with occurrence of paroxysmal supraventricular tachycardia or atrial fibrillation: A transtelephonic monitoring studyAmerican Heart Journal, 1992
- Epidemiologic assessment of chronic atrial fibrillation and risk of strokeNeurology, 1978
- A computer model of atrial fibrillationAmerican Heart Journal, 1964